Attachment 3. 60-Day FRN 0920-06BL

40721

Federal Register / Vol. 71, No. 137 / Tuesday, July 18, 2006 / Notices
send comments to Seleda Perryman,
CDC Assistant Reports Clearance
Officer, 1600 Clifton Road, MS–D74,
Atlanta, GA 30333 or send an e-mail to
[email protected].
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.

involving individual Federal Reserve
System employees.
2. Any items carried forward from a
previously announced meeting.
FOR FURTHER INFORMATION CONTACT:
Michelle Smith, Director, or Dave
Skidmore, Assistant to the Board, Office
of Board Members at 202–452–2955.
SUPPLEMENTARY INFORMATION: You may
call 202–452–3206 beginning at
approximately 5 p.m. two business days
before the meeting for a recorded
announcement of bank and bank
holding company applications
scheduled for the meeting; or you may
contact the Board’s Web site at http://
www.federalreserve.gov for an electronic
announcement that not only lists
applications, but also indicates
procedural and other information about
the meeting.
Board of Governors of the Federal Reserve
System, July 14, 2006.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 06–6351 Filed 7–14–06; 2:44 pm]

Proposed Project
Evaluation of the HIV Testing Social
Marketing Campaign (HTSMC)—New—
National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention
(NCHHSTP), Coordinating Center for
Infectious Diseases (CCID), Centers for
Disease Control and Prevention (CDC).

BILLING CODE 6210–01–S

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Background and Brief Description
This project involves the evaluation of
the HIV Testing Social Marketing
Campaign (HTSMC), a CDC-sponsored
social marketing campaign aimed at
increasing HIV testing rates among
young, single, African American
women. The CDC has designed an
efficacy study to evaluate the HTSMC
and its messages under controlled
conditions. The study entails selecting a
sample of single African American
females, ages 18 to 34, with less than 4
years of college education and collecting
baseline data on their knowledge,
attitudes, beliefs, intentions, and
behaviors related to HIV testing. The
study represents an ‘‘efficacy’’
methodology in that participants will be
divided into treatment and control

Centers for Disease Control and
Prevention
[60Day-06–06BL]

Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 and

conditions. Participants in the treatment
condition, will be exposed to campaign
materials including radio
advertisements, a billboard, and an
informational booklet that will be
distributed over the Internet. Thus the
study participants’ exposure will occur
under controlled conditions, without
the distractions and variability of
potential exposure in the real world. As
part of the advertisement stimuli
package, the billboard advertisement
will appear as part of the online log-in
for each stimuli session in order to
simulate the appearance of a sign.
Therefore, we do not estimate any
additional burden for exposure to the
billboard advertisement.
Key outcomes related to the HTSMC
will be measured in two follow-up
surveys. The first follow-up survey will
occur 2 weeks after the baseline survey.
The second follow-up survey will occur
6 weeks after the baseline survey.
Comparisons of changes in these
outcomes would then be made between
participants in the treatment and control
conditions. Findings from this study
will be used by CDC and its partners to
inform current and future program
activities.
We expect a total of 1,630 participants
to complete the baseline survey. The
1,630 participants who complete the
baseline survey will be randomly
assigned to the treatment or control
condition. 815 participants (the
treatment condition) will be exposed to
the radio ad and booklet. Of the 1,630
participants who completed the baseline
survey, we expect 1,140 to complete the
first follow-up survey. Of the 1,140 who
complete the first follow-up survey, we
expect 800 to complete the second
follow-up survey, which will have fewer
questions than the first follow-up survey
because it will only pertain to questions
about behavior change and selected
behavioral intentions.
There are no costs to the respondents
other than their time.

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

wwhite on PROD1PC61 with NOTICES

Respondents

Responses
per
respondent

Baseline survey .............................................................................................................
Radio ad stimuli viewing ...............................................................................................
Booklet reading .............................................................................................................
Follow-up survey 1 ........................................................................................................
Follow-up survey 2 ........................................................................................................

1,630
815
815
1,140
800

1
1
1
1
1

Total .......................................................................................................................

....................

....................

VerDate Aug<31>2005

18:27 Jul 17, 2006

Jkt 208001

PO 00000

Frm 00036

Fmt 4703

Sfmt 4703

E:\FR\FM\18JYN1.SGM

18JYN1

Average
burden per
response (in
hours)
15/60
18/60
15/60
15/60
5/60
......................

Total
burden
hours
408
245
204
285
67
1,209

40722

Federal Register / Vol. 71, No. 137 / Tuesday, July 18, 2006 / Notices

Dated: July 10, 2006.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E6–11340 Filed 7–17–06; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004D–0333]

Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Draft Guidance:
Emergency Use Authorization of
Medical Products
AGENCY:

Food and Drug Administration,

HHS.
ACTION:

Notice.

SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by August 17,
2006.
ADDRESSES: OMB is still experiencing
significant delays in the regular mail,
including first class and express mail,
and messenger deliveries are not being
accepted. To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–4659.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.

wwhite on PROD1PC61 with NOTICES

Draft Guidance: Emergency Use
Authorization of Medical Products
The Federal Food, Drug, and Cosmetic
Act (the act) permits the Commissioner
of FDA (the Commissioner) to authorize
the use of unapproved medical products
or unapproved uses of approved
medical products during an emergency
declared under section 564 of the act (21
U.S.C. 360bbb–3). The data to support
issuance of an emergency use

VerDate Aug<31>2005

16:25 Jul 17, 2006

Jkt 208001

authorization (EUA) must demonstrate
that, based on the totality of the
scientific evidence available to the
Commissioner, including data from
adequate and well-controlled clinical
trials (if available), it is reasonable to
believe that the product may be effective
in diagnosing, treating, or preventing a
serious or life-threatening disease or
condition (21 U.S.C. 360bbb–3(c)).
Although the exact type and amount of
data needed to support an EUA may
vary depending on the nature of the
declared emergency and the nature of
the candidate product, FDA
recommends that a request for
consideration for an EUA include
scientific evidence evaluating the
product’s safety and effectiveness,
including the adverse event profile for
diagnosis, treatment, or prevention of
the serious or life-threatening disease or
condition, as well as data and other
information on safety, effectiveness,
risks and benefits, and (to the extent
available) alternatives.
Under section 564 of the act, the
Commissioner may establish conditions
on the approval of an EUA. Section
564(e) requires the Commissioner (to the
extent practicable given the
circumstances of the emergency) to
establish certain conditions on an
authorization that the Commissioner
finds necessary or appropriate to protect
the public health and permits the
Commissioner to establish other
conditions that he finds necessary or
appropriate to protect the public health.
Conditions authorized by section 564(e)
of the act include, for example:
Requirements for information
dissemination to health care providers
or authorized dispensers and product
recipients; adverse event monitoring
and reporting; data collection and
analysis; recordkeeping and records
access; restrictions on product
advertising, distribution, and
administration; and limitations on good
manufacturing practices requirements.
Some conditions, the statute specifies,
are mandatory to the extent practicable
for authorizations of unapproved
products and discretionary for
authorizations of unapproved uses of
approved products. Moreover, some
conditions may apply to manufacturers
of an EUA product, while other
conditions may apply to any person
who carries out any activity for which
the authorization is issued. Section 564
of the act also gives the Commissioner
authority to establish other conditions
on an authorization that the
Commissioner finds to be necessary or
appropriate to protect the public health.
For purposes of estimating the burden
of reporting, FDA has established six

PO 00000

Frm 00037

Fmt 4703

Sfmt 4703

categories of respondents which
include: (1) Those who file a Request for
Consideration for an EUA after a
determination of actual or potential
emergency and, in lieu of submitting the
data, provide reference to a pending or
approved application; (2) those who file
a Request for Consideration for an EUA
and the data after a determination of
actual or potential emergency, without
reference to a pending or approved
application; (3) those who submit data
to FDA on a candidate EUA product,
which is subject to a pending or
approved application, prior to a
determination of actual or potential
emergency; (4) those who submit data to
FDA prior to a determination of actual
or potential emergency about a
candidate EUA product for which there
is no pending or approved application;
(5) manufacturers of an unapproved
EUA product who must report to FDA
regarding such activity; and (6) State
and local public health officials who
carry out an activity related to an
unapproved EUA product (e.g.,
administering the product to civilians)
and who must report to FDA regarding
such activity.
For purposes of estimating the burden
of recordkeeping, FDA has calculated
the anticipated burden on
manufacturers of unapproved products
authorized for emergency use. The
agency anticipates that the Federal
Government will perform some of the
additional recordkeeping necessary for
unapproved products (e.g., related to the
administration of unapproved EUA
products to military personnel). FDA
also anticipates that some State and
local public health officials may be
required to perform additional
recordkeeping (e.g., related to the
administration of unapproved EUA
products to civilians) and calculated a
recordkeeping burden for those
activities.
No burden was attributed to reporting
or recordkeeping for unapproved uses of
approved products, because those
products already are subject to approved
collections of information (adverse
experience reporting for biological
products is approved under OMB
control number 0910–0308 through May
31, 2005; adverse drug experience
reporting is approved under OMB
control number 0910–0230 through
September 30, 2005; and investigational
new drug applications (IND) regulations
are approved under OMB control
number 0910–0014 through January 31,
2006), and any additional burden
imposed by this proposed collection
would be minimal. Thus, FDA estimates
the burden of this collection of
information as follows:

E:\FR\FM\18JYN1.SGM

18JYN1